Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Capecitabine as Adjuvant Therapy for Nasopharyngeal Carcinoma
NCT05201859Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2022
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started May 2022; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05201859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201859.